Literature DB >> 33484425

Protein-bound uremic toxin lowering strategies in chronic kidney disease: a systematic review and meta-analysis.

Kullaya Takkavatakarn1, Thunyatorn Wuttiputinun1, Jeerath Phannajit1, Kearkiat Praditpornsilpa1, Somchai Eiam-Ong1, Paweena Susantitaphong2,3.   

Abstract

INTRODUCTION: Accumulation of protein-bound uremic toxins, including indoxyl sulfate and p-cresyl sulfate, are associated with increased cardiovascular disease and mortality in chronic kidney disease (CKD). We performed a systematic review and meta-analysis to synthesize the available strategies for lowering protein-bound uremic toxin levels in CKD patients.
METHODS: We conducted a meta-analysis by searching the databases of MEDLINE, Scopus, and the Cochrane Central Register of Controlled Trials for observational studies and randomized controlled trials (RCTs) that examined the effect of dietary protein restrictions, biotic supplements (including prebiotics, probiotics, and synbiotics), AST-120, dialysis techniques, and the outcome of preservation of residual renal function (RRF) on indoxyl sulfate and p-cresyl sulfate levels. Random-effect model meta-analyses were used to compute changes in the outcomes of interest.
RESULTS: A total of 38 articles (2,492 patients), comprising 28 RCTs, 8 single-arm or prospective cohort studies, and 2 cross-sectional studies were included in this meta-analysis. When compared with placebo, prebiotics, synbiotics, and AST-120 provided significantly lower levels of both serum indoxyl sulfate and p-cresyl sulfate. There were no significant reductions in serum indoxyl sulfate and p-cresyl sulfate levels in patients receiving probiotics. Preservation of RRF in dialysis patients resulted in lower levels of both of the protein-bound uremic toxins. When compared with conventional hemodialysis, hemodiafiltration significantly decreased serum p-cresyl sulfate alone, whereas a significant change in serum indoxyl sulfate levels was observed only in studies with long-term observation periods. Very low protein diet (VLPD) and other oral medications yielded insignificant differences in protein-bound uremic toxins.
CONCLUSIONS: The present meta-analysis demonstrated that prebiotics, synbiotics, and AST-120 can effectively reduce both serum indoxyl sulfate and p-cresyl sulfate in CKD patients when compared with placebo. Preservation of RRF was associated with lower serum indoxyl sulfate and p-cresyl sulfate levels. The effect of biotic supplements was detected only in dialysis patients. For non-dialysis CKD patients, the results were limited due to the small number of studies. Further studies are needed to determine the efficacy in these populations.
© 2021. Italian Society of Nephrology.

Entities:  

Keywords:  Chronic kidney disease; Indoxyl sulfate; Protein-bound uremic toxins; p-Cresyl sulfate

Mesh:

Substances:

Year:  2021        PMID: 33484425     DOI: 10.1007/s40620-020-00955-2

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  46 in total

1.  Assessing the quality of randomized trials: reliability of the Jadad scale.

Authors:  H D Clark; G A Wells; C Huët; F A McAlister; L R Salmi; D Fergusson; A Laupacis
Journal:  Control Clin Trials       Date:  1999-10

Review 2.  Review on uremic toxins: classification, concentration, and interindividual variability.

Authors:  Raymond Vanholder; Rita De Smet; Griet Glorieux; Angel Argilés; Ulrich Baurmeister; Philippe Brunet; William Clark; Gerald Cohen; Peter Paul De Deyn; Reinhold Deppisch; Beatrice Descamps-Latscha; Thomas Henle; Achim Jörres; Horst Dieter Lemke; Ziad A Massy; Jutta Passlick-Deetjen; Mariano Rodriguez; Bernd Stegmayr; Peter Stenvinkel; Ciro Tetta; Christoph Wanner; Walter Zidek
Journal:  Kidney Int       Date:  2003-05       Impact factor: 10.612

3.  Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses.

Authors:  Andreas Stang
Journal:  Eur J Epidemiol       Date:  2010-07-22       Impact factor: 8.082

4.  [Normal indicators of the cardiovascular system in laboratory animals (rats)].

Authors:  I V Muzurov; V N Vlasov; N Iu Roshchevskaia
Journal:  Gig Sanit       Date:  1989-02

5.  Intensive Hemodialysis Fails to Reduce Plasma Levels of Uremic Solutes.

Authors:  Tammy L Sirich; Timothy W Meyer
Journal:  Clin J Am Soc Nephrol       Date:  2018-02-14       Impact factor: 8.237

Review 6.  Indoxyl sulfate is a nephro-vascular toxin.

Authors:  Toshimitsu Niwa
Journal:  J Ren Nutr       Date:  2010-09       Impact factor: 3.655

7.  The uremic retention solute p-cresyl sulfate and markers of endothelial damage.

Authors:  Björn K I Meijers; Soetkin Van Kerckhoven; Kristin Verbeke; Wim Dehaen; Yves Vanrenterghem; Marc F Hoylaerts; Pieter Evenepoel
Journal:  Am J Kidney Dis       Date:  2009-07-17       Impact factor: 8.860

Review 8.  Protein-bound uremic toxins: a long overlooked culprit in cardiorenal syndrome.

Authors:  Suree Lekawanvijit; Andrew R Kompa; Henry Krum
Journal:  Am J Physiol Renal Physiol       Date:  2016-05-04

9.  Chronic kidney disease-induced cardiac fibrosis is ameliorated by reducing circulating levels of a non-dialysable uremic toxin, indoxyl sulfate.

Authors:  Suree Lekawanvijit; Andrew R Kompa; Minako Manabe; Bing H Wang; Robyn G Langham; Fuyuhiko Nishijima; Darren J Kelly; Henry Krum
Journal:  PLoS One       Date:  2012-07-19       Impact factor: 3.240

Review 10.  Meta-Analysis of the Associations of p-Cresyl Sulfate (PCS) and Indoxyl Sulfate (IS) with Cardiovascular Events and All-Cause Mortality in Patients with Chronic Renal Failure.

Authors:  Cheng-Jui Lin; Vincent Wu; Pei-Chen Wu; Chih-Jen Wu
Journal:  PLoS One       Date:  2015-07-14       Impact factor: 3.240

View more
  7 in total

Review 1.  Diverse roles of microbial indole compounds in eukaryotic systems.

Authors:  Prasun Kumar; Jin-Hyung Lee; Jintae Lee
Journal:  Biol Rev Camb Philos Soc       Date:  2021-06-17

2.  Protection of Residual Renal Function and Nutritional Treatment: First Step Strategy for Reduction of Uremic Toxins in End-Stage Kidney Disease Patients.

Authors:  Adamasco Cupisti; Piergiorgio Bolasco; Claudia D'Alessandro; Domenico Giannese; Alice Sabatino; Enrico Fiaccadori
Journal:  Toxins (Basel)       Date:  2021-04-19       Impact factor: 4.546

3.  Protein-Bound Uremic Toxins Lowering Effect of Sevelamer in Pre-Dialysis Chronic Kidney Disease Patients with Hyperphosphatemia: A Randomized Controlled Trial.

Authors:  Kullaya Takkavatakarn; Pongpratch Puapatanakul; Jeerath Phannajit; Warumphon Sukkumme; Pajaree Chariyavilaskul; Patita Sitticharoenchai; Asada Leelahavanichkul; Pisut Katavetin; Kearkiat Praditpornsilpa; Somchai Eiam-Ong; Paweena Susantitaphong
Journal:  Toxins (Basel)       Date:  2021-09-27       Impact factor: 4.546

4.  Effects of AST-120 on muscle health and quality of life in chronic kidney disease patients: results of RECOVERY study.

Authors:  Ran-Hui Cha; Seok Hui Kang; Mi Yeun Han; Won Suk An; Su-Hyun Kim; Jun Chul Kim
Journal:  J Cachexia Sarcopenia Muscle       Date:  2021-12-03       Impact factor: 12.910

Review 5.  Microbial-Derived Tryptophan Catabolites, Kidney Disease and Gut Inflammation.

Authors:  Avra Melina Madella; Jeroen Van Bergenhenegouwen; Johan Garssen; Rosalinde Masereeuw; Saskia Adriana Overbeek
Journal:  Toxins (Basel)       Date:  2022-09-18       Impact factor: 5.075

6.  An Innovative Synbiotic Formulation Decreases Free Serum Indoxyl Sulfate, Small Intestine Permeability and Ameliorates Gastrointestinal Symptoms in a Randomized Pilot Trial in Stage IIIb-IV CKD Patients.

Authors:  Carmela Cosola; Maria Teresa Rocchetti; Ighli di Bari; Paola Maria Acquaviva; Valentina Maranzano; Simone Corciulo; Agostino Di Ciaula; Domenica Maria Di Palo; Flavia Maria La Forgia; Sergio Fontana; Maria De Angelis; Piero Portincasa; Loreto Gesualdo
Journal:  Toxins (Basel)       Date:  2021-05-05       Impact factor: 4.546

Review 7.  Removal of Protein-Bound Uremic Toxins Using Binding Competitors in Hemodialysis: A Narrative Review.

Authors:  Vaibhav Maheshwari; Xia Tao; Stephan Thijssen; Peter Kotanko
Journal:  Toxins (Basel)       Date:  2021-09-04       Impact factor: 4.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.